Business
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
VANCOUVER, BC / ACCESS Newswire / December 10, 2025 / Lir Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new comparative cell-penetrating peptide-based uptake study (the ...
About this update from Lir Life Sciences Corp.
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / December 10, 2025 / Lir Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new comparative cell-penetrating peptide-based uptake study (the "Study") of GLP/GIP[1]-based obesity therapies, further advancing its novel transdermal platform for obesity and metabolic disease. This initiative is intended to further the Company's research and development of patient-friendly, needle-free delivery options for incretin therapies. The Company believes that transdermal systems have the potential to improve comfort, accessibility, and long-term treatment adherence for individuals managing chronic metabolic conditions and evidence-based weight-loss treatments.","length":795,"tagName":"p"},{"type":"text","content":"GLP, specifically GLP-1, and GIP act through complementary biological pathways that together can potentially improve glucose metabolism, energy balance, and weight regulation. By targeting both metabolic and appetite-related mechanisms, these hormones have the potential to address key drivers of obesity.[2]","length":308,"tagName":"p"},{"type":"text","content":"In collaboration with its scientific partners, Lir Life Sciences has designed a controlled animal Study to evaluate the novel transdermal uptake of GLP/GIP-based obesity therapies using novel cell-penetrating peptide (CPP) formulations. In the investigation, Study subjects will be pre-treated with transdermal formulations of each drug, followed by an oral glucose challenge. Delivery effectiveness will be assessed by measuring blood glucose levels following a glucose intake. The Study will also compare the efficiency of transdermal delivery with standard subcutaneous injections. In practical terms, this means the research team will assess how effectively each molecule permeates the skin and supports glucose control relative to traditional injectable administration.","length":774,"tagName":"p"},{"type":"text","content":"This comparative work is designed to map the performance envelope of Lir's CPP-enhanced transdermal platform across multiple GLP/GIP-based therapies and to inform future research and development priorities, including which molecules are best suited for needle-free delivery and subsequent Investigational New Drug (IND)-e...